References
Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-Aselective antagonist. J Med Chem 1997 May 23; 40: 1690–7
Texas biotechnology completes phase I safety trial for oral endothelin antagonist. PR Newswire [online].: Available from: URL: http://www.newspage.com [Accessed 1997 Dec 12]
Texas Biotechnology Corporation. Texas Biotechnology presents clinical results on its endothelin A receptor antagonist, TBC11251, at AHA sessions [media release]. 1998 Nov 10
Givertz M, Colucci WS, Gottlieb SS, et al. Acute ET(A) receptor blockade reduces pulmonary vascular resistance in patients with chronic heart failure. Circulation 1998 Oct 27; 98 Suppl.: 578
Rights and permissions
About this article
Cite this article
TBC 11251. Drugs R&D 2, 38–39 (1999). https://doi.org/10.2165/00126839-199902010-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902010-00011